J Mov Disord.  2024 Jan;17(1):82-88. 10.14802/jmd.23042.

Parkinson’s Disease, Impulsive-Compulsive Behaviors, and Health-Related Quality of Life

• Grall-Bronnec M
• Verholleman A
• Victorri-Vigneau C
• Leboucher J
• Thiabaud E
• Hardouin JB
• Schreck B
• Rouaud T
• Roy M
• Derkinderen P
• Challet-Bouju G

• KMID: 2551214
• DOI: http://doi.org/10.14802/jmd.23042

Abstract

Objective
A large body of literature has examined the links between the use of dopamine replacement therapy (DRT) in Parkinson’s disease (PD) and the development of “impulsive-compulsive behaviors (ICBs).” Little is known regarding the link between the development of ICBs and health-related quality of life (HRQOL). We aimed to explore the factors that are associated with poorer HRQOL, especially in relation to DRT-induced ICBs, in a sample of PD patients.
Methods
This PARKADD (PARK: PARKinson’s disease; ADD: behavioral ADDictions) study was a prospective case‒control study initially designed to assess the factors associated with ICBs in PD patients. A prospective clinical follow-up was added, aiming to capture the long-term evolution of HRQOL in relation to ICBs occurring or worsening after the beginning of PD. We focused on sociodemographic and PD characteristics and the history or presence of ICBs. HRQOL was measured using the Parkinson’s Disease Questionnaire-8. A multivariate linear regression was performed to identify factors related to poorer HRQOL.
Results
A total of 169 patients were eligible for the follow-up study. The presence of an ICB, a higher levodopa equivalent daily dose (LEDD) and a longer PD duration were significantly associated with poorer HRQOL, with an interaction between LEDD and PD duration.
Conclusion
The presence of an ICB was related to poorer HRQOL and should be considered a crucial factor for the management of PD patients. Several studies were recently published that provide guidelines for the management of these patients, with recommendations based on two key principles: prevention and specific treatment.

Keyword

Parkinson’s disease; Impulse control disorder; Behavioral addiction; Dopamine replacement therapy; Health-related quality of life; L-DOPA equivalent daily dose